Tuberculous Meningitis Clinical Trial
Official title:
Diagnostic Accuracy of Imaging Findings in Tubercular Meningitis/Spinal Tubercular Arachnoiditis and Correlation With Outcomes in Patients With Tubercular Meningitis, Spinal Tubercular Arachnoiditis
The goal of this Diagnostic accuracy study is - To study sensitivity and specificity of sulcal tuberculomas in the diagnosis of tubercular meningitis and - To study the correlation of imaging findings in tubercular meningitis and spinal tubercular arachnoiditis with clinical outcomes after completion of therapy - Secondary objectives - To study the proportion of patients having clinical or imaging features of spinal tubercular arachnoiditis - To study the factors determining outcomes in patients with spinal tubercular arachnoiditis - To study the treatment trends in patients with spinal tubercular arachnoiditis The investigators will include [study Population] Patients with chronic meningitis as per criteria listed below - Chronic meningitis : Case definition - Headache with or without fever, nuchal stiffness and systemic symptoms AND - CSF suggestive of meningitis Pleocytosis (>20 cells per μL) with lymphocyte predominance (>50%) OR Protein concentration greater than age-specific normal value; especially >1•0 g/L OR Glucose concentration less than 60% of concentration in blood OR MRI suggestive of meningeal enhancement on contrast enhanced T1 sequences AND - Deemed by the treating physician that the syndrome is consistent with chronic meningitis - Patients who are positive for antibodies to HIV and pregnant females will also be included. - Willing to undergo periodic assessment clinically and with MRI as per clinical condition demands. The sensitivity and specificity of the finding of sulcal tuberculomas will be compared to the reference standard diagnostic criteria for the diagnosis of TB meningitis.
Status | Recruiting |
Enrollment | 120 |
Est. completion date | February 2024 |
Est. primary completion date | January 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 14 Years and older |
Eligibility | - Patients attending Neurology OPD or are admitted in General Medicine or Geriatric medicine or Medical oncologywards with chronic meningitis diagnosed on the basis of composite clinical criteria, imaging criteria as well as natural history of the illness - Atleast 14 years of age of all sexes Willing to undergo periodic assessment clinically and with MRI as per clinical condition demands. Exclusion Criteria: Not willing to provide consent |
Country | Name | City | State |
---|---|---|---|
India | All India Institute of Medical Sciences, New Delhi | New Delhi | Delhi |
Lead Sponsor | Collaborator |
---|---|
All India Institute of Medical Sciences, New Delhi |
India,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Sensitivity and specificity of sulcal tuberculomas in the diagnosis of tubercular meningitis | Sensitivity and specificity of sulcal tuberculomas compared with reference standard clinical composite criteria | Day 1 of diagnosis or imaging acquisition | |
Primary | Correlation of imaging findings with clinical outcomes | Correlation of imaging findings in tubercular meningitis and spinal tubercular arachnoiditis with clinical outcomes after completion of therapy The outcome parameters of interest will be modified Rankin scale, visual acuity at 3 months and end of therapy. | 6 months to 18 months, average 9 months after starting treatment | |
Secondary | Clinical or imaging features of spinal tubercular arachnoiditis | Proportion of patients having clinical or imaging features of spinal tubercular arachnoiditis | Day 1 of diagnosis or imaging acquisition | |
Secondary | Factors determining outcomes in patients with spinal tubercular arachnoiditis | Factors determining outcomes in patients with spinal tubercular arachnoiditis | 6 months to 18 months, average 9 months after starting treatment | |
Secondary | Treatment trends in patients with spinal tubercular arachnoiditis | Treatment trends in patients with spinal tubercular arachnoiditis | 6 months to 18 months, average 9 months after starting treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01371916 -
Diagnosis of Tuberculous Meningitis by ESAT-6 in CSF
|
N/A | |
Active, not recruiting |
NCT00433719 -
Immediate Versus Deferred Antiretroviral Therapy for HIV-Associated Tuberculous Meningitis
|
N/A | |
Completed |
NCT02237365 -
A Pilot Study of Adjunctive Aspirin for the Treatment of HIV Negative Adults With Tuberculous Meningitis
|
Phase 2 | |
Not yet recruiting |
NCT02588196 -
The Relationships Between Gene Polymorphisms of LTA4H and Dexamethasone Treatment for Tuberculous Meningitis
|
Phase 4 | |
Completed |
NCT03092817 -
Adjunctive Corticosteroids for Tuberculous Meningitis in HIV-infected Adults (The ACT HIV Trial)
|
Phase 3 | |
Recruiting |
NCT03787940 -
Optimizing Antituberculosis Therapy in Adults With Tuberculous Meningitis
|
N/A | |
Not yet recruiting |
NCT05917340 -
Intensified Short Course Regimen for TBM in Adults
|
Phase 3 | |
Completed |
NCT01802502 -
Rifampicin Explorative PK Study for Tuberculous Meningitis Comparing Oral and Intravenous Preparation
|
Phase 2 | |
Recruiting |
NCT03898635 -
Retrospective Real-word Study of Linezolid for the Treatment of Tuberculous Meningitis
|
||
Completed |
NCT05781646 -
Xpert MTB/RIF Assay for Diagnosis of Tuberculous Meningitis (TBM) in Maharaj Nakorn Chiang Mai Hospital
|
N/A | |
Active, not recruiting |
NCT03100786 -
Leukotriene A4 Hydrolase Stratified Trial of Adjunctive Corticosteroids for HIV-uninfected Adults With Tuberculous Meningitis
|
Phase 3 | |
Recruiting |
NCT04145258 -
Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis
|
Phase 3 | |
Recruiting |
NCT05383742 -
Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis
|
Phase 2 | |
Completed |
NCT03226379 -
Driving Reduced AIDS-associated Meningo-encephalitis Mortality
|
N/A | |
Recruiting |
NCT05590455 -
Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis
|
Phase 2 | |
Recruiting |
NCT04308928 -
Evaluation of New Biomarker-based Approaches for Improving the Diagnosis of Childhood Tuberculous Meningitis
|